Tag: TNBC
FDA Approves Sacituzumab Govitecan for Adult Patients with Unresectable Locally Advanced...
This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...
Everest Medicines to Initiate a Registration Study in China for Sacituzumab...
China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...
Boehringer Ingelheim Venture Fund and PPF Group Close a US $...
Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Ladiratuzumab Vedotin (SGN-LIV1A) in Triple Negative Breast Cancers Shows a 29%...
Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple...
Seattle Genetics has signed a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug conjugate...
Sacituzumab Govitecan Show Promising Results in Patients with Advanced Triple-negative Breast...
A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on...
SGN-LIV1A Monotherapy Data Show 37% ORR in Heavily Pretreated Triple Negative...
Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...
New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program
Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...
